137 related articles for article (PubMed ID: 24393871)
1. [Neoadjuvant chemotherapy with capecitabine plus oxaliplatin and bevacizumab for the treatment of patients with resectable metastatic colorectal cancer].
Kemmochi T; Egawa T; Mihara K; Ito Y; Ohkubo Y; Mori T; Nagashima A; Makino H; Yamamuro W
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1629-31. PubMed ID: 24393871
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open-label, single-arm, noncomparative trial.
Chen HH; Lin JK; Chen JB; Chuang CH; Liu MC; Wang JY; Changchien CR
Asia Pac J Clin Oncol; 2018 Feb; 14(1):61-68. PubMed ID: 28906589
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Saltz L
J Clin Oncol; 2008 Apr; 26(12):2006-12. PubMed ID: 18421053
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
Waddell T; Gollins S; Soe W; Valle J; Allen J; Bentley D; Morris J; Lloyd A; Swindell R; Taylor MB; Saunders MP
Cancer Chemother Pharmacol; 2011 May; 67(5):1111-7. PubMed ID: 20676676
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial.
Yalcin S; Uslu R; Dane F; Yilmaz U; Zengin N; Buyukunal E; Buyukberber S; Camci C; Sencan O; Kilickap S; Ozdener F; Cevik D
Oncology; 2013; 85(6):328-35. PubMed ID: 24247559
[TBL] [Abstract][Full Text] [Related]
6. XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study.
Rosati G; Avallone A; Aprile G; Butera A; Reggiardo G; Bilancia D
Cancer Chemother Pharmacol; 2013 Jan; 71(1):257-64. PubMed ID: 23100174
[TBL] [Abstract][Full Text] [Related]
7. [Phase I / II study of XELOX plus bevacizumab in Japanese patients with metastatic colorectal cancer(JO19380)].
Sato A; Doi T; Boku N; Kato K; Komatsu Y; Yamaguchi K; Muro K; Hamamoto Y; Koizumi W; Mizunuma N; Takiuchi H
Gan To Kagaku Ryoho; 2011 Apr; 38(4):561-9. PubMed ID: 21498982
[TBL] [Abstract][Full Text] [Related]
8. [Tolerability of XELOX in postoperative adjuvant chemotherapy for colorectal cancer].
Matsuda C; Danno K; Miyazaki S; Fujitani K; Kubota M; Kawada J; Takagi M; Fukui A; Iwase K; Tanaka Y
Gan To Kagaku Ryoho; 2014 Jun; 41(6):743-7. PubMed ID: 25129086
[TBL] [Abstract][Full Text] [Related]
9. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
Cassidy J; Tabernero J; Twelves C; Brunet R; Butts C; Conroy T; Debraud F; Figer A; Grossmann J; Sawada N; Schöffski P; Sobrero A; Van Cutsem E; Díaz-Rubio E
J Clin Oncol; 2004 Jun; 22(11):2084-91. PubMed ID: 15169795
[TBL] [Abstract][Full Text] [Related]
10. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.
Díaz-Rubio E; Tabernero J; Gómez-España A; Massutí B; Sastre J; Chaves M; Abad A; Carrato A; Queralt B; Reina JJ; Maurel J; González-Flores E; Aparicio J; Rivera F; Losa F; Aranda E;
J Clin Oncol; 2007 Sep; 25(27):4224-30. PubMed ID: 17548839
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer.
Muñoz A; Pericay C; García-Girón C; Alonso V; Dueñas R; Cirera L; Rivera F; Falcó E; Bustos IA; Salud A
Oncol Res; 2013; 21(4):181-91. PubMed ID: 24762224
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.
Doi T; Boku N; Kato K; Komatsu Y; Yamaguchi K; Muro K; Hamamoto Y; Sato A; Koizumi W; Mizunuma N; Takiuchi H
Jpn J Clin Oncol; 2010 Oct; 40(10):913-20. PubMed ID: 20462981
[TBL] [Abstract][Full Text] [Related]
13. Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer.
Watanabe K; Kawahara H; Enomoto H; Toyama Y; Akiba T; Yanaga K
Anticancer Res; 2013 Sep; 33(9):4029-32. PubMed ID: 24023346
[TBL] [Abstract][Full Text] [Related]
14. Xelox (capecitabine plus oxaliplatin) as neoadjuvant chemotherapy of unresectable liver metastases in colorectal cancer patients.
Coskun U; Buyukberber S; Yaman E; Uner A; Er O; Ozkan M; Dikilitas M; Oguz M; Yildiz R; B DY; Kaya AO; Benekli M
Neoplasma; 2008; 55(1):65-70. PubMed ID: 18190244
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer.
Hasegawa J; Nishimura J; Mizushima T; Miyake Y; Kim HM; Takemoto H; Tamagawa H; Noura S; Fujii M; Fujie Y; Kato T; Miwa H; Takemasa I; Ikeda M; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
Cancer Chemother Pharmacol; 2014 May; 73(5):1079-87. PubMed ID: 24595805
[TBL] [Abstract][Full Text] [Related]
16. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.
Wong R; Cunningham D; Barbachano Y; Saffery C; Valle J; Hickish T; Mudan S; Brown G; Khan A; Wotherspoon A; Strimpakos AS; Thomas J; Compton S; Chua YJ; Chau I
Ann Oncol; 2011 Sep; 22(9):2042-2048. PubMed ID: 21285134
[TBL] [Abstract][Full Text] [Related]
17. Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study.
Pilancı KN; Saglam S; Okyar A; Yucel S; Pala-Kara Z; Ordu C; Namal E; Ciftci R; Iner-Koksal U; Kaytan-Saglam E
Cancer Chemother Pharmacol; 2016 Jul; 78(1):143-50. PubMed ID: 27270460
[TBL] [Abstract][Full Text] [Related]
18. [Results of adjuvant chemotherapy (XELOX) of advanced colorectal cancer].
Eropkin PV; Rybakov EG; Kashnikov VN; Panina MV
Vopr Onkol; 2011; 57(2):179-83. PubMed ID: 21809662
[TBL] [Abstract][Full Text] [Related]
19. A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer.
Zhi J; Chen E; Major P; Burns I; Robinson B; McKendrick J; Rittweger K; Abt M; Goldstein D
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1199-206. PubMed ID: 21409383
[TBL] [Abstract][Full Text] [Related]
20. Two Doses of oxaliplatin with capecitabine (XELOX) in metastatic colorectal cancer.
Moreno-Solórzano I; Ibeas-Rollan R; Monzó-Planella M; Moreno-Solórzano J; Martínez-Ródenas F; Pou-Sanchis E; Hernández-Borlan R; Navarro-Vigo M; Ortigosa-Rodríguez S; Gel-Moreno B
Clin Colorectal Cancer; 2007 Sep; 6(9):634-40. PubMed ID: 17945035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]